N Vidal, E Brunet-Gouet, S Frileux, B Aouizerate, V Aubin, R Belzeaux, P Courtet, T D'Amato, C Dubertret, B Etain, E Haffen, D Januel, M Leboyer, A Lefrere, P M Llorca, E Marlinge, E Olié, M Polosan, R Schwan, M Walter, C Passerieux, P Roux
Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals with remitted BD. Moreover, the validity of only one anticholinergic burden scale designed to assess the anticholinergic load of medications has been tested in BD...
September 21, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology